The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 19, 2021
Filed:
Apr. 13, 2017
Applicant:
Cellectis, Paris, FR;
Inventors:
Julien Valton, New York, NY (US);
Veronique Zennou, Jersey City, NJ (US);
Philippe Duchateau, Draveil, FR;
Laurent Poirot, Paris, FR;
Assignee:
CELLECTIS, Paris, FR;
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); C12N 15/113 (2010.01); A61P 31/00 (2006.01); A61K 48/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0091 (2013.01); A61K 35/17 (2013.01); A61K 48/0008 (2013.01); A61K 48/0058 (2013.01); A61K 48/0066 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 15/113 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01);
Abstract
The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.